MarketPulse

pharmaceutical company

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

XORTX Shareholders Back 5-to-1 Consolidation to Avert NASDAQ Delisting

XORTX shareholders approved a 5-to-1 share consolidation to maintain NASDAQ compliance, reducing shares from 6.96M to 1.39M ahead of April 2026 deadline.
XRTXkidney diseaseshare consolidation
The Motley FoolThe Motley Fool··Adé Hennis

Maze Therapeutics President Liquidates Full Position Ahead of Q4 Earnings

Maze Therapeutics president Harold Bernstein sold all 30,000 shares for $1.51M via pre-arranged trading plan, weeks before Q4 earnings report.
MAZEclinical-stage biotechearnings report
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aquestive Names New Chief Legal Officer as Braender Transitions to Corporate Secretary

Aquestive Therapeutics appoints Day Pitney partner Thomas Zalewski as Chief Legal Officer and Chief Compliance Officer, with Lori Braender transitioning to Corporate Secretary after eight years.
AQSTCorporate Secretaryleadership transition
GlobeNewswire Inc.GlobeNewswire Inc.··Xortx Therapeutics Inc.

XORTX Wins ISS Backing for Share Consolidation Plan Ahead of March Vote

XORTX Therapeutics secures ISS endorsement for share consolidation, with proxy advisor backing March 2026 shareholder vote. ISS cited no direct shareholder value impact while noting improved financing prospects.
XRTXkidney diseaseshare consolidation
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Soleno Therapeutics Faces Class Action Over DCCR Safety Claims as Stock Plummets 27%

Robbins LLP launches class action against $SLNO over alleged investor deception regarding DCCR drug safety and efficacy for Prader-Willi syndrome treatment.
EOSEDRVNSLNOclass action lawsuitstock decline
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Amarin's Vascepa Faces Generic Onslaught: Single-Drug Dependency Poses Existential Risk

Amarin's sole drug Vascepa faces generic competition, causing revenue to plummet 36% to $183 million in 2025, raising serious concerns about the company's single-product vulnerability.
PFEAMRNrevenue declinerestructuring
BenzingaBenzinga··Prnewswire

Viatris Reaffirms Annual Dividend Commitment With $0.48 Per Share Policy

Viatris reaffirms $0.48 annual dividend per share for 2026, declaring $0.12 quarterly payout. Marks sixth consecutive year of consistent shareholder distributions.
VTRSquarterly dividendshareholder returns
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aquestive Therapeutics to Present at Four Major Healthcare Investor Conferences in March

Aquestive Therapeutics will present at four major healthcare investor conferences in March 2026, updating investors on its clinical pipeline and strategic initiatives.
AQSTinvestor conferencespharmaceutical company